United States

Analyst Research Report Snapshot


Chugai Pharmaceutical Co., Ltd.






06 Jul 2015





Companies referenced:


Available for Immediate Download

Chugai Pharmaceutical Co., Ltd. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company. Features: - Detailed information on Chugai Pharmaceutical Co., Ltd. required for business and competitor intelligence needs - A study of the major internal and external factors affecting Chugai Pharmaceutical Co., Ltd. in the form of a SWOT analysis - An in-depth view of the business model of Chugai Pharmaceutical Co., Ltd. including a breakdown and examination of key business segments - Intelligence on Chugai Pharmaceutical Co., Ltd.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Chugai Pharmaceutical Co., Ltd., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Chugai Pharmaceutical Co., Ltd. (Chugai or 'the company'), the Japanese subsidiary of the Roche Group, is engaged in biopharmaceutical research and development. It produces antibody drugs primarily focusing on oncology, renal diseases and bone and joint diseases. The company operates in Europe, the Americas and Asia Pacific. It is headquartered in Tokyo, Japan, and employed 6,872 people as of December 31, 2013. The company recorded revenues of JPY423,652 million (approximately $4,363.6 million) during the financial year ended December 2013 (FY2013), an increase of 9.6% over FY2012. The operating profit of the company was JPY78,738 million (approximately $811 million) in FY2013, an increase of 5.5% over FY2012. The net profit was JPY50,895 million (approximately $524.2 million) in FY2013, an increase of 10.5% over FY2012. Reasons to Purchase: - Gain understanding of Chugai Pharmaceutical Co., Ltd. and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Chugai Pharmaceutical Co., Ltd. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Chugai Pharmaceutical Co., Ltd.’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.